Questions around this news
What did VERAXA report from its first in vivo BiTAC-ADC study?
The release says a single 3 mg/kg dose was associated with significant tumor regression in a breast cancer model, with no observed decrease in body weight. It also reports that both components of the BiTAC-ADC were needed for the intended tumor-specific response. These findings were presented at the 17th World ADC Congress.
What is an antibody-drug conjugate?
An antibody-drug conjugate is a therapy that links an antibody to a drug payload. The antibody is designed to bind a target, while the attached payload acts on cells. The design aims to bring the drug to cells bearing the target, though the performance and safety of each conjugate depend on its specific components and behavior in the body.
What is the difference between in vivo and in vitro research?
In vivo research is conducted in a living organism, while in vitro research is performed outside an organism, often using cells or other biological material in a laboratory setting. The approaches can provide different kinds of evidence: laboratory experiments can examine specific interactions, while in vivo studies show how effects unfold in a whole biological system.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response.
Additional in vitro studies demonstrated the platform’s ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor and target multiple cancer cell lines. The findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates while offering a differentiated safety profile designed to reduce systemic toxicity.
To view the full press release, visit https://ibn.fm/cs8SW
About VERAXA Biotech AG
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]
In brief
VERAXA Biotech says it presented initial in vivo proof-of-concept results and additional laboratory findings for its BiTAC-ADC platform at the 17th World ADC Congress in San Diego. In a breast cancer model, a single 3 mg/kg dose was associated with tumor regression, with no decrease in body weight observed. The company also reports that both components of the platform were needed for the intended tumor-specific response. In vitro studies indicated that BiTAC-ADCs could distinguish cancer cells from healthy cells, limit active toxin release outside tumors and act on multiple cancer cell lines. VERAXA says the findings support further evaluation of the platform’s potential efficacy and safety characteristics compared with conventional antibody-drug conjugates.
Key takeaways
- VERAXA presented its first in vivo proof-of-concept results for the BiTAC-ADC platform.
- A single 3 mg/kg dose was associated with tumor regression in a breast cancer model, with no observed body-weight decrease.
- The company says both BiTAC-ADC components were needed for the intended tumor-specific response.
- In vitro results included cancer-cell distinction, limited toxin release outside tumors and activity across multiple cancer cell lines.
SEC filings
Earlier from VERAXA Biotech AG
- VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
- VERAXA Biotech (NASDAQ: VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress
- VERAXA Biotech (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
- VERAXA Biotech (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
- VERAXA Biotech (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy
